Abstract
Depression is a common neuropsychiatric manifestation among Alzheimer’s disease (AD) patients. It may compromise everyday activities and lead to a faster cognitive decline as well as worse quality of life. The identification of promising biomarkers may therefore help to timely initiate and improve the treatment of preclinical and clinical states of AD, and to improve the long-term functional outcome. In this narrative review, we report studies that investigated biomarkers for AD-related depression. Genetic findings state AD-related depression as a rather complex, multifactorial trait with relevant environmental and inherited contributors. However, one specific set of genes, the brain derived neurotrophic factor (BDNF), specifically the Val66Met polymorphism, may play a crucial role in AD-related depression. Regarding neuroimaging markers, the most promising findings reveal structural impairments in the cortico-subcortical networks that are related to affect regulation and reward / aversion control. Functional imaging studies reveal abnormalities in predominantly frontal and temporal regions. Furthermore, CSF based biomarkers are seen as potentially promising for the diagnostic process showing abnormalities in metabolic pathways that contribute to AD-related depression. However, there is a need for standardization of methodological issues and for replication of current evidence with larger cohorts and prospective studies.
Keywords: Alzheimer’s disease, depression, biomarkers, depression in Alzheimer´s Disease, neuroimaging, neurophysiology, genetics, serum biomarkers, BDNF.
Current Alzheimer Research
Title:Integrated Biomarkers for Depression in Alzheimer’s Disease: A Critical Review
Volume: 14 Issue: 4
Author(s): Sofia Wenzler, Christian Knochel, Ceylan Balaban, Dominik Kraft, Juliane Kopf, Gilberto S. Alves, David Prvulovic, Andre F. Carvalho and Viola Oertel-Knochel
Affiliation:
Keywords: Alzheimer’s disease, depression, biomarkers, depression in Alzheimer´s Disease, neuroimaging, neurophysiology, genetics, serum biomarkers, BDNF.
Abstract: Depression is a common neuropsychiatric manifestation among Alzheimer’s disease (AD) patients. It may compromise everyday activities and lead to a faster cognitive decline as well as worse quality of life. The identification of promising biomarkers may therefore help to timely initiate and improve the treatment of preclinical and clinical states of AD, and to improve the long-term functional outcome. In this narrative review, we report studies that investigated biomarkers for AD-related depression. Genetic findings state AD-related depression as a rather complex, multifactorial trait with relevant environmental and inherited contributors. However, one specific set of genes, the brain derived neurotrophic factor (BDNF), specifically the Val66Met polymorphism, may play a crucial role in AD-related depression. Regarding neuroimaging markers, the most promising findings reveal structural impairments in the cortico-subcortical networks that are related to affect regulation and reward / aversion control. Functional imaging studies reveal abnormalities in predominantly frontal and temporal regions. Furthermore, CSF based biomarkers are seen as potentially promising for the diagnostic process showing abnormalities in metabolic pathways that contribute to AD-related depression. However, there is a need for standardization of methodological issues and for replication of current evidence with larger cohorts and prospective studies.
Export Options
About this article
Cite this article as:
Wenzler Sofia, Knochel Christian, Balaban Ceylan, Kraft Dominik, Kopf Juliane, Alves S. Gilberto, Prvulovic David, Carvalho F. Andre and Oertel-Knochel Viola, Integrated Biomarkers for Depression in Alzheimer’s Disease: A Critical Review, Current Alzheimer Research 2017; 14 (4) . https://dx.doi.org/10.2174/1567205013666160603011256
DOI https://dx.doi.org/10.2174/1567205013666160603011256 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel Neuroendocrine and Metabolic Mechanism Provides the Patented Platform for Important Rejuvenation Therapies: Targeted Therapy of Telomere Attrition and Lifestyle Changes of Telomerase Activity with the Timing of Neuron-Specific Imidazole-Containing Dipeptide-Dominant Pharmaconutrition Provision
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Oxidative Stress in Cardiovascular Disease: A New Avenue Toward Future Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Editorial [ NeuroAIDS: A Neuroscience Problem with Global Impact ]
Current HIV Research Blood-based Amyloid and Tau Biomarker Tests For Alzheimer’s Disease
Neuroscience and Biomedical Engineering (Discontinued) A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases
Current Pharmaceutical Design Effective Inhibition of Foam Cells Formation by Tanshinone IIA in RAW264.7 Macrophages Induced with LDL Isolated from Hypercholesterolemia Patients: A Proteomic Analysis
Current Proteomics Alzheimer’s Disease, Astrocytes and Kynurenines
Current Alzheimer Research Assessing Schizophrenia-relevant Cognitive and Social Deficits in Mice: A Selection of Mouse Behavioral Tasks and Potential Therapeutic Compounds
Current Pharmaceutical Design Insights Into the Molecular Aspects of Neuroprotective Bacoside A and Bacopaside I
Current Neuropharmacology Radix Angelica Sinensis that Contains the Component Z-Ligustilide Promotes Adult Neurogenesis to Mediate Recovery from Cognitive Impairment
Current Neurovascular Research What Can Imaging Reveal about Obesity and the Brain?
Current Alzheimer Research A Series of Novel Neuroprotective Blood Brain Barrier Penetrating Flavonoid Drugs to Treat Acute Ischemic Stroke
Current Pharmaceutical Design Recent Advances in the Treatment of Neurogenic Erectile Dysfunction
Recent Patents on CNS Drug Discovery (Discontinued) HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research Phytochemical Informatics and Virtual Screening of Herbs Used in Chinese Medicine
Current Pharmaceutical Design Modulation of Anxiety Behavior by Intranasally Administered Vaccinia Virus Complement Control Protein and Curcumin in a Mouse Model of Alzheimers Disease
Current Alzheimer Research Molecular Function of Tocopherols in Age Related Diseases
Current Pharmaceutical Design The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Soothing the Inflamed Brain: Effect of Non-Steroidal Anti-Inflammatory Drugs on Alzheimers Disease Pathology
CNS & Neurological Disorders - Drug Targets Potential Novel Treatments for Bipolar Depression: Ketamine, Fatty Acids, Anti-inflammatory Agents, and Probiotics
CNS & Neurological Disorders - Drug Targets